EMA issues advice on use of regdanvimab for treating COVID-19

Following a review of the data, the European Medicines Agency has concluded that regdanvimab is appropriate for the treatment of confirmed COVID-19 in adult patients who do not require supplemental oxygen therapy and are at high risk of progressing to severe COVID-19.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news